LUYE PHARMA (02186.HK) Stock Community - Hot Topic Discussions

Quote List Quote List

Event Tracking

Dec4

Qilu Pharmaceutical Proactively Lowers Price of Aflibercept to Capture Market Share

12:11

Nov24

Luye Pharmaceutical's New Drug LY03017 Receives FDA Clinical Trial Approval

00:12

Nov20

Lu Ye Pharmaceutical Issued $150 Million Exchangeable Preferred Shares

23:19

Nov2

Pharmaceutical Companies Participate in Commercial Insurance Innovative Drug Catalog Price Negotiations

07:20

Oct27

Luye Pharma Group Conducting Phase I Clinical Study for LY03017

18:07

Sep29

Huansan Securities Maintains Buy Rating for Luoxi Pharmaceutical

02:13

Schedules & Filings

Schedules

Filings

Aug28

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 1.741 B, Net Income 171.23 M, EPS 0.0455

Mar30

Earning Release(CST)

FY2024 Q4 Earning Release (HKD) Revenue 1.589 B, Net Income 44.71 M, EPS 0.0118

Aug28

Earning Release(CST)

FY2024 Q2 Earning Release (HKD) Revenue 1.652 B, Net Income 208.37 M, EPS 0.0553

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change